24 results
Chapter 26 - Functional MR imaging in presurgical planning
- from Section 3 - Adult neoplasia
- Edited by Jonathan H. Gillard, University of Cambridge, Adam D. Waldman, Imperial College London, Peter B. Barker, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Neuroimaging
- Published online:
- 05 March 2013
- Print publication:
- 26 November 2009, pp 380-404
-
- Chapter
- Export citation
-
Summary
Introduction
Cortical mapping during surgical craniotomy in awake and cooperative patients was introduced almost a century ago, at the beginning of the twentieth century, but was rarely used until relatively recently, when the development of MRI-guided neuronavigational and MRI-based functional and anatomical mapping techniques made the accuracy of the functional localization afforded by cortical mapping more relevant. Modern neuroimaging provides morphological, metabolic, and functional measurements that may guide and refine surgical treatment. Functional MRI (fMRI) and MR tractography can establish the relationship between the margin of the lesion and the surrounding functionally viable brain tissue. Therefore, increasingly, accurate estimates of procedural risks and prognosis are potentially available to the neurosurgeon before surgery.
Mapping brain function
Historical review
The observation that a focal brain lesion may cause a behavioral or motor deficit was alluded to in an Egyptian papyrus that has been dated to roughly 2500 BC It is possible that Imhotep, a military surgeon at the time of the pyramids, was the author of this detailed clinical report on 27 cases with head injury.[1] It was at the time of the Alexandria Medical School in the third century BC that Erofilo from Calcedonia (Turkey), an early anatomist, suggested that the brain harbors motor, sensory, and cognitive functions. However, at the time of the Roman Empire, Claudio Galen (129–201 AD) thought that the three main mental functions (motor, sensory, and thought/memory) were localized in the cerebral ventricles, not in the brain tissue. Abu Ali Ibn Abdallah Ibn Sina (980–1037), also known as Avicenna, spread Galen’s theories throughout the Arab world. Avicenna also believed that the three main functions were localized in the ventricles. The movement of fluid from one ventricle to the next was hypothesized to mediate the transfer from one function to another: imagination was localized in the lateral ventricles, rational thinking in the third ventricle, and memory in the fourth ventricle. It was Costanzo Varolio (1543–1575) who advanced the notion that the brain parenchyma itself subserves higher cognitive functions. Thomas Willis (1621–1675), the English anatomist and surgeon, localized memory to the cortical gray matter, imagination in the white matter, perception and movement in the striatum, and involuntary actions to the cerebellum and brainstem.
Chapter 53 - Magnetic resonance spectroscopy of inborn errors of metabolism
- from Section 8 - Pediatrics
- Edited by Jonathan H. Gillard, University of Cambridge, Adam D. Waldman, Imperial College London, Peter B. Barker, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Neuroimaging
- Published online:
- 05 March 2013
- Print publication:
- 26 November 2009, pp 823-842
-
- Chapter
- Export citation
-
Summary
Genetics of metabolic diseases
Hereditary inborn errors of metabolism are the results of an enzyme defect involving one or more metabolic pathways. An enzymatic block may act by inducing deficiency of metabolites normally produced beyond the block, by interfering with other metabolic pathways as a result of deviation from normal to accessory or normally unused pathways, by producing accumulation of substances that may interfere with the cell’s function and/or survival, or by interfering in various ways with other essential metabolic processes. Classic genetic disorders are caused by an abnormality in a single gene or may be multifactorial. In addition there are other more recently described categories, such as mitochondrial inheritance, fragile site, and genomic imprinting. Most metabolic diseases are inherited according to single-gene Mendelian mode of inheritance. The inheritance of the phenotypic set follows the Mendelian rules of inheritance: autosomal dominant, autosomal recessive, or X-linked. Canavan (17p), Krabbe (14q), Gaucher (1q), galactosemia (9p), Hallervorden–Spatz (20p), and Wilson (13q) diseases are examples of autosomal recessive single-gene disorders. Adrenoleukodystrophy (ALD), Aicardi syndrome, and Pelizaeus–Merzbacher disease (PMD) are examples of X-linked single-gene disorders. The incidence of single-gene disorders is between 2 and 3% by the age of 1 year, closer to 5% by the age of 25 years.[1] Newborn screening programs are available for single-gene disorders that respond well to dietary therapy, such as phenylalanine hydroxylase deficiency (phenylketonuria [PKU]), galactosemia, and maple syrup urine disease (MSUD). The completion of the Human Genome Mapping Project will make it possible to screen the population for many other single-gene disorders. This novel possibility raises many ethical and legal questions that have yet to be addressed.[2]
Chromosomes are the structures in which genes are packaged. Chromosome disorders are the result of either deficiency or excess of chromosomal material. It is estimated that approximately 5 in 1000 live newborns will have a chromosome abnormality. Deficiency or excess of chromosomal material can be the result of a change in chromosome number (polyploidy, aneuploidy) or in structure.
13 - MRS in breast cancer
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 229-242
-
- Chapter
- Export citation
-
Summary
Key points
MRS of the breast is more technically demanding than that in the brain.
Cho levels have been reported to be higher in malignant breast cancer than in benign lesions and normal breast tissue.
Early decreases in Cho signal intensity may be seen in lesions that respond to treatment.
MRS is limited by sensitivity to lesions at least 1 cm3.
Inadequate sensitivity may lead to false negatives, and both false positives and negatives may arise due to insufficient water and lipid suppression, or other artifacts.
Introduction: MRS of breast tissues
Although the vast majority of magnetic resonance spectroscopy (MRS) studies in humans have been performed to date in the central nervous system, there is growing interest in the application of MRS to other organ systems in the body. This is particularly true for areas such as breast cancer, where conventional diagnostic techniques have relatively limited sensitivity and/or specificity. MRS of the breast presents a number of technical challenges (described in detail later in this chapter) which are gradually being overcome, allowing clinical research studies to be performed. Early MRS studies of human breast cancer focused on the phosphorus (31P) nucleus, since localized, water-suppressed proton spectroscopy was not available at that time. However, with the development of improved gradient hardware, spatial localization, and water suppression techniques, 31P spectroscopy has largely been replaced by proton (1H) MRS. The much higher sensitivity of the proton nucleus allows spectra with higher signal-to-noise ratios (SNR) to be recorded from smaller volumes of tissue compared to 31P.
10 - MRS in traumatic brain injury
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 161-179
-
- Chapter
- Export citation
-
Summary
Key points
TBI is a major cause of morbidity in young adults and children.
Low levels of NAA and, if seen, increased lactate, in the early stage of injury are prognostic of poor outcome.
Other common metabolic abnormalities in TBI (most of which also correlate with poor outcome) include increased levels of choline, myo-inositol, and glutamate plus glutamine.
Metabolic abnormalities are observed with MRS in regions of the brain with normal appearance in conventional MRI.
MRI and MRS are difficult to perform in acutely ill TBI patients: MRS may be more feasible in mild TBI patients for the purpose of predicting long-term cognitive deficits.
The role of MRS in guiding TBI therapy is unknown.
The comparative value of MRS compared to other advanced imaging modalities remains to be determined.
Introduction
Traumatic brain injury (TBI) is a leading cause of death and lifelong disability among children and young adults across the developed world. TBI is estimated to result in greater than $60 billion in direct and indirect annual costs due to health care and work loss disability. The Centers for Disease Control and Prevention (CDC) estimate that each year approximately 1.4 million Americans survive a TBI, among whom approximately 235,000 are hospitalized. Approximately 80,500 new TBI survivors are left each year with residual deficits consequent to their injury, which lead to long-term disabilities that may or may not be improved through rehabilitation. In 2001, 157,708 people died from acute traumatic injury, which accounted for about 6.5% of all deaths in the United States.
12 - MRS in prostate cancer
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 212-228
-
- Chapter
- Export citation
-
Summary
Key points
Prostate cancer has a high incidence, and is one of the leading causes of death in men.
The sensitivity and specificity of diagnosing prostate cancer with conventional imaging methods (ultra sound, MRI) is relatively low.
The normal prostate contains high levels of citrate (Cit) which can be detected in the proton spectrum at 2.6 ppm. Other compounds detectable in vivo include creatine, choline, spermine, and lipids.
Citrate is a strongly coupled mutiple at 1.5 and 3.0 T. For optimum detection, careful attention to pulse sequence parameters (TR, TE) is required. TE 120 ms is commonly used at 1.5 T, and TE 75–100 ms at 3 T.
Multiple studies have reported that prostate cancer is associated with decreased levels of citrate and increased levels of Cho, compared to both normal prostate and also benign prostatic hyperplasia (BPH).
MRS and MRSI of the prostate is technically challenging: water- and lipid-suppressed 3D-MRSI is the method of choice for most prostate spectroscopy studies.
Some studies report that adding MRSI to conventional MRI increases sensitivity and specificity of prostate cancer diagnosis.
MRSI is traditionally performed with an endorectal surface coil, but acceptable quality data may be obtained at 3 T with external phased-array coils which are more comfortable for patients.
2 - Pulse sequences and protocol design
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 19-33
-
- Chapter
- Export citation
1 - Introduction to MR spectroscopy in vivo
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 1-18
-
- Chapter
- Export citation
9 - MRS in neurodegenerative disease
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 144-160
-
- Chapter
- Export citation
-
Summary
Key points
Despite the relatively common occurrence of neurodegenerative diseases, MRS is lightly used in these conditions, most likely because of lack of sensitivity and overlap of spectral findings in different disorders.
MRS usually shows decreased levels of NAA in dementia.
Dementias associated with gliosis (e.g. Alzheimer's) also have increased myo-inositol (mI).
mI/NAA ratios correlate with clinical severity and histopathological involvement in Alzheimer's disease.
mI/NAA ratios, and regional variations in metabolite levels, may be helpful in the differential diagnosis of different dementias (Alzheimer, vascular, frontotemporal, Lewy body).
Parkinson's disease does not seem to be associated with any metabolic disorders, although other Parkinsonian disorders (e.g. multiple system atrophy) may show reduced NAA in the basal ganglia.
Metabolic changes in Huntington's disease are unclear; some studies have reported elevated lactate levels in the basal ganglia, but others have not.
Prion diseases are characterized by decreased NAA levels.
In amyotrophic lateral sclerosis (ALS), upper motor neuron NAA decreases may be helpful in establishing a diagnosis.
Introduction
Neurodegenerative diseases include a very wide group of disorders affecting the central nervous system (CNS). Many of these disorders arise from the combined effects of genetic predisposition and environmental factors. This results in reduced cognition (e.g. Alzheimer's disease, dementia with Lewy bodies, and vascular dementia), motor system performance (e.g. amyotrophic lateral sclerosis), or both (e.g. Parkinson's disease and prion diseases).
Acknowledgments
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp viii-viii
-
- Chapter
- Export citation
Clinical MR Spectroscopy
- Techniques and Applications
- Peter B. Barker, Alberto Bizzi, Nicola De Stefano, Rao Gullapalli, Doris D. M. Lin
-
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009
-
In vivo magnetic resonance spectrosopy (MRS) is increasingly being used in the clinical setting, particularly for neurological disorders. Clinical MR Spectroscopy – Techniques and Applications explains both the underlying physical principles of MRS and provides a perceptive review of clinical MRS applications. Topics covered include an introduction to MRS physics, information content of spectra from different organ systems, spectral analysis methods, recommended protocols and localization techniques, and normal age- and region-related spectral variations in the brain. Clinical applications in the brain are discussed for brain tumors, hypoxic and ischemic injury, infectious, inflammatory and demyelinating diseases, epilepsy, neurodegenerative disorders, trauma and metabolic diseases. Outside of the brain, techniques and applications are discussed for MRS in the musculosketal system, breast and prostate. Written by leading MRS experts, this is an invaluable guide for anyone interested in in vivo MRS, including radiologists, neurologists, neurosurgeons, oncologists and medical researchers.
Frontmatter
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp i-iv
-
- Chapter
- Export citation
8 - MRS in epilepsy
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 131-143
-
- Chapter
- Export citation
-
Summary
Key points
MRS is principally used as an adjunct diagnostic technique for evaluating patients with medically intractable epilepsy (in order to identify the seizure focus).
Most commonly, NAA is reduced in epileptogenic tissue; metabolic abnormalities are often subtle.
Metabolic abnormalities may be more widespread than seen on MRI, and present in the contralateral hemisphere.
MRS may occasionally be helpful when other techniques (e.g. MRI) are either normal or non-specific.
MRS measures of the inhibitory neurotransmitter GABA using spectral editing may help determine optimal drug regimen.
MRS may also be a useful research tool for determining epileptogenic networks in the brain.
Introduction
Epilepsy, the condition of recurrent seizures, is a relatively common neurological disorder, estimated to affect between 1 and 2 million people in the US alone. A multitude of etiologies cause epilepsy, including tumors, developmental abnormalities, febrile illness, trauma, or infection. However, not infrequently, the cause is unknown. Many patients with epilepsy can be successfully treated pharmacologically, but when medical management fails to adequately control seizure activity, surgical resection of the epileptogenic tissue may be considered. For surgery to be successful, seizures must be of focal onset from a well-defined location. It has been estimated that up to 10% of patients with epilepsy are medically intractable, of whom approximately 20% may be candidates for surgical treatment. Traditionally, scalp electroencephalography (EEG) and often invasive (subdural grid or depth electrode) EEG are used to identify the epileptogenic regions of the brain, but increasingly magnetic resonance imaging (MRI), positron emission tomography (PET), ictal single photon emission computed tomography (SPECT), and, more recently, magnetoencephalography (MEG) are also used.
4 - Normal regional variations: brain development and aging
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 51-60
-
- Chapter
- Export citation
-
Summary
Key points
Substantial regional variations in proton brain spectra exist; differences between gray and white matter, anterior–posterior gradients, and differences between the supra- and infra-tentorial brain are common.
Spectra change rapidly over the first few years of life; at birth, NAA is low, and choline and myo-inositol are high. By about 4 years of age, spectra from most regions have a more “adult-like” appearance.
In normal development, only subtle age-related changes are found between the ages of 4 and 20 years.
In normal aging, only subtle age-related changes are found. A recent meta-analysis indicated the most common findings are mildly increased choline and creatine in frontal brain regions of elderly subjects (> 68 years), and stable or slightly decreasing (parietal regions only) NAA.
Introduction
Interpretation of spectra from patients with neuropathology requires a knowledge of the normal regional and age-related spectral variations seen in the healthy brain. This is a difficult issue, since spectra are quite dependent on the technique used to record them (particularly choice of echo time, and field strength), and also show quite large regional and age-related (at least in young children) dependencies. However, while there still remain some gaps in the literature (e.g. detailed, regional studies in very young children), for the most part regional and age-related changes in brain spectra are now well-characterized. This chapter reviews what is known about regional metabolite variations, as well as metabolic changes associated with brain development, and aging.
7 - MRS in infectious, inflammatory, and demyelinating lesions
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 110-130
-
- Chapter
- Export citation
-
Summary
Key points
MRS can provide useful clinical, metabolic information in infection, inflammation, and demyelination.
Pyogenic abscess have a unique metabolic pattern with decreased levels of all normally observed brain metabolites, and elevation of succinate, alanine, acetate, and amino acids, as well as lipids and lactate. This pattern is quite distinct from that seen in brain tumors.
Tuberculomas are characterized by elevated lipid and an absence of all other resonances.
MRS is extensively used in research studies of HIV infection; early changes include elevated choline and myo-inositol perhaps associated with microglial proliferation, while later changes (associated with cognitive impairment, and dementia) include reduced NAA (neuronal loss).
MRS may also be useful in assisting differential diagnosis in HIV-associated lesions.
MRS shows decreased NAA (suggesting axonal dysfunction and loss) in early multiple sclerosis, as well as increased Cho and myo-inositol and lipids (suggesting demyelination). NAA correlates with clinical disability. White matter that appears normal on T2 MRI may be abnormal metabolically in MS. Lactate may be elevated in acute, inflammatory demyelination.
Acute disseminated encephalomyelitis (ADEM) may show similar spectral patterns to MS; however, ADEM with good clinical outcome usually only shows mild NAA losses in lesions.
Introduction
Intracranial infection, inflammation, and demyelination include a wide range of disorders of the central nervous system (CNS). Magnetic resonance imaging (MRI) plays a crucial role in the diagnosis and therapeutic decision making in these diseases.
3 - Spectral analysis methods, quantitation, and common artifacts
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 34-50
-
- Chapter
- Export citation
-
Summary
Key points
Correct post-processing and quantitation are key aspects of in vivo MRS.
Filtering, phase-correction and baseline correction improve MRS data.
Peak area estimation can be done using parametric or non-parametric routines in either the time domain or frequency domains.
“LCModel” software is becoming widely used and accepted, particularly for single-voxel MRS data.
MRSI processing requires additional steps; k-space filtering and other manipulations can improve MRSI data quality.
A variety of strategies are available for quantitation, based on either internal or external reference standards, or phantom replacement methodology.
Quantitation routines should take into account voxel composition, particularly the amount of CSF partial volume present.
MRS is sensitive to field inhomogeneity and other artifacts.
Introduction
Methods for spectral analysis and the quantitative analysis of spectral data are arguably as important as the techniques used to collect the data; the use of incorrect analysis methods can lead to systematic errors or misinterpretation of spectra. In general, the ultimate goal of spectral analysis is to determine the concentrations of the compounds present in the spectra. In MRS, the area under the spectral peak is proportional to the metabolite concentration; however, determining the proportionality constant can be challenging. In addition, peak area measurements in in-vivo spectroscopy are complicated by resonance overlap, baseline distortions, and lineshapes that often only poorly approximate conventional models such as Gaussian or Lorentzian functions. Therefore, quantitative analysis of in vivo MRS data is challenging. This chapter reviews basic spectral processing techniques, methods for determining peak areas, and strategies for calculating metabolite concentrations.
14 - MRS in musculoskeletal disease
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 243-255
-
- Chapter
- Export citation
-
Summary
Key points
31P-MRS allows the detection of phosphate-containing metabolites that are central to energy metabolism, and therefore is particularly suitable for studying muscle physiology and its disorders in vivo.
Time-resolved signals from inorganic phosphates, phosphocreatine, phosphodiesters/monoesters, and intermediates of ATP reflect physiologic changes in muscles during rest, exercise, and recovery.
Quantitative analysis of metabolites allows estimates of cytosolic ADP based on a number of assumptions, and the recovery of ADP has been used as a measure of in vivo mitochondrial function.
In pathologic states including metabolic (mitochondrial or glycolytic pathway) dysfunction, hereditary and acquired myopathies, 31P-MRS shows biochemical alterations (reduced PCr, increased Pi, slow ADP recovery) that tend to overlap between pathologies.
Glycogenolytic disorders (such as McArdle's disease) may show paradoxical alkalosis during exercise.
Muscle 31P-MRS is valuable in monitoring therapeutic response in a number of neuromuscular disorders.
1H-MRS currently has a limited role in the clinical evaluation of musculoskeletal disease, but has been used as a research tool to assess intramyocellular lipid, which has been implicated in skeletal muscle insulin resistance and type 2 diabetes mellitus.
Introduction
Magnetic resonance spectroscopy (MRS) of skeletal muscle has been studied over several decades. In particular, muscle MRS has been utilized to study carbohydrate metabolism (by 13-carbon (13C) MRS), lipid metabolism (by proton (1H) MRS) and, more widely, energy metabolism (by 31-phosphorus (31P) MRS).
Index
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 256-264
-
- Chapter
- Export citation
11 - MRS in cerebral metabolic disorders
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp 180-211
-
- Chapter
- Export citation
-
Summary
Key points
MR spectroscopy is a valuable tool to direct biochemistry work-up of patients with inborn errors of metabolism.
Multivoxel MR spectroscopic imaging is the best method to study the heterogeneous anatomic distribution of metabolic diseases.
The interpretation of MR spectra and MR images together increases diagnostic accuracy.
Abnormal MR spectral peaks are diagnostic of a few hereditary metabolic disorders.
Lactate is elevated in about half of patients with mitochondrial disorders, in most patients with leukoencephalopathies with demyelination or rarefaction of white matter, and in few with organic acidopathies targeting the subcortical gray matter nuclei.
In patients with leukoencephalopathy, H-MRSI is a valuable tool for identifying one of the following three underlying tissue pathophysiologies: hypomyelination, demyelination, and rarefaction of white matter.
MRS may be useful to monitor response to therapy when available.
Introduction
The advent of magnetic resonance (MR) imaging has changed the clinical approach to the evaluation of metabolic disorders. MR imaging is highly sensitive and plays a prominent role in the diagnostic evaluation of patients with metabolic disorders of the central nervous system (CNS). However, the structural and signal abnormalities detected on conventional MR imaging are often not specific enough to suggest a definite diagnosis in many of these complex disorders.
With advances in MR technology, proton MR spectroscopy (1H-MRS) has become more widely available, and now it can be performed with conventional MR imaging in the same study session. Nowadays, a complete imaging exam lasts no longer than 30 min at 1.5 Tesla or higher magnetic fields.
Abbreviations
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp ix-x
-
- Chapter
- Export citation
Preface
- Peter B. Barker, The Johns Hopkins University School of Medicine, Alberto Bizzi, Nicola De Stefano, Università degli Studi, Siena, Rao Gullapalli, University of Maryland, Baltimore, Doris D. M. Lin, The Johns Hopkins University School of Medicine
-
- Book:
- Clinical MR Spectroscopy
- Published online:
- 04 August 2010
- Print publication:
- 12 November 2009, pp vii-vii
-
- Chapter
- Export citation
-
Summary
Magnetic resonance spectroscopy (MRS) allows the non-invasive measurement of selected biological compounds in vivo. Feasibility was first demonstrated in humans in the mid-1980s. Since that time, much experience has been accumulated with the use of MRS in both research and clinical applications. Nearly all magnetic resonance imaging (MRI) scanners have the capability to perform MRS, and MRS techniques still continue to improve, even after two decades of development. MRS has been applied to the study of all major pathologies, particularly in the brain, but has also found application in other organ systems as well, most notably in the breast and prostate.
In spite of this considerable research effort and the unique biochemical information provided, only limited integration of MRS into clinical practice has occurred to date. There are multiple reasons for this, including non-standardization of acquisition and analysis protocols, limited vendor support, difficulties in interpretation (particularly for radiologists without a background in MRS), limited perceived “added-value” above conventional MRI, and lack of reimbursement.
This book is intended to address some of these issues. It gives the reader a solid basis for understanding both the techniques and applications of clinical MRS. Recommendations are made for MRS protocols, and information provided on normal regional- and age-related metabolic variations in the brain. Detailed information about the role of MRS in evaluating pathologies involving the central nervous system, breast, prostate, and musculoskeletal systems is provided.